MAPK10 and early-onset autosomal dominant Alzheimer disease: Although the cause of AD, which affects many, is not clearly identified, many therapeutic agents have been studied to inhibit the formation of these two hallmarks, and we aim to develop a treatment for Alzheimer’s disease that targets and inhibits JNK3, which is deeply involved in the formation of amyloid β protein and NFT [2].